Edgestream Partners L.P. Sells 59,627 Shares of Prestige Consumer Healthcare Inc. $PBH

Edgestream Partners L.P. trimmed its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 35.4% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 108,814 shares of the company’s stock after selling 59,627 shares during the quarter. Edgestream Partners L.P.’s holdings in Prestige Consumer Healthcare were worth $6,449,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of PBH. Lido Advisors LLC boosted its position in Prestige Consumer Healthcare by 5.4% during the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after purchasing an additional 192 shares in the last quarter. Cerity Partners LLC lifted its position in shares of Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after buying an additional 218 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after buying an additional 236 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in shares of Prestige Consumer Healthcare by 19.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company’s stock worth $91,000 after buying an additional 249 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Zacks Research lowered shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Finally, Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average price target of $70.75.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Trading Down 4.2%

Shares of NYSE:PBH opened at $49.98 on Friday. Prestige Consumer Healthcare Inc. has a 52-week low of $42.62 and a 52-week high of $75.63. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 1.68 and a beta of 0.35. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The business has a 50-day moving average price of $48.25 and a 200-day moving average price of $56.52.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The firm had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. Prestige Consumer Healthcare’s quarterly revenue was down 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).